Gene · 1294
Papers2,575
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,575
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review of the Literature. | J Drugs Dermatol | 2025 | 40196952 | PubTator, text mining | PubMed |
| The Application of DNA Viruses to Biotechnology. | Viruses | 2025 | 40143341 | PubTator, text mining | PubMed |
| A 37-year-old Woman with a Solitary Flaccid Bulla on the Left Wrist: A Quiz. | Acta Derm Venereol | 2025 | 40135356 | PubTator, text mining | PubMed |
| Taking care of patients with recessive dystrophic epidermolysis bullosa from birth to adulthood: a multidisciplinary Italian Delphi consensus. | Orphanet J Rare Dis | 2025 | 40091088 | PubTator, text mining | PubMed |
| Porous Silicon Nanoneedles Efficiently Deliver Adenine Base Editor to Correct a Recurrent Pathogenic COL7A1 Variant in Recessive Dystrophic Epidermolysis Bullosa. | Adv Mater | 2025 | 40072288 | PubTator, text mining | PubMed |
| The Role of Fibroblasts in Dystrophic Epidermolysis Bullosa Pathogenesis and Current Treatment Approaches. | JID Innov | 2025 | 40061239 | PubTator, text mining | PubMed |
| COL7A1 indicates crucial potential as a basal membrane-related prognostic biomarker and therapeutic target in lung adenocarcinoma. | Front Pharmacol | 2025 | 40028167 | PubTator, text mining | PubMed |
| Enhanced HDR-mediated correction of heterozygous COL7A1 mutations for recessive dystrophic epidermolysis bullosa. | Mol Ther Nucleic Acids | 2025 | 40027886 | PubTator, text mining | PubMed |
| Molecular insights into genodermatoses: Genetic findings from 43 patients. | Arch Dermatol Res | 2025 | 40025372 | PubTator, text mining | PubMed |
| Phenotypic Characteristics of a Patient Cohort With Recessive Dystrophic Epidermolysis Bullosa and the Pathogenic Variant c.7485+5G>A in Intron 98 of COL7A1. | Am J Med Genet A | 2025 | 40013374 | PubTator, text mining | PubMed |
| Spatial transcriptomics reveals prognostically LYZ+ fibroblasts and colocalization with FN1+ macrophages in diffuse large B-cell lymphoma. | Cancer Immunol Immunother | 2025 | 39998673 | PubTator, text mining | PubMed |
| Recombinant human collagen XVII protects skin basement membrane integrity by inhibiting the MAPK and Wnt signaling pathways. | Mol Med Rep | 2025 | 39981899 | PubTator, text mining | PubMed |
| Decoding COL7A1: a genetic roadmap to prognostication and personalized medicine in recessive dystrophic epidermolysis bullosa. | Br J Dermatol | 2025 | 39946286 | PubTator, text mining | PubMed |
| Coding Genes Helped the Origination and Diversification of Intragenic MicroRNAs. | Mol Biol Evol | 2025 | 39932914 | PubTator, text mining | PubMed |
| Dystrophic epidermolysis bullosa - From biochemistry to interventions. | Matrix Biol | 2025 | 39922469 | PubTator, text mining | PubMed |
| A pathogenic COL7A1 variant highlights semi-dominant inheritance in dystrophic epidermolysis bullosa. | BMC Med Genomics | 2025 | 39905456 | PubTator, text mining | PubMed |
| A Novel COL7A1 Mutation in a Patient With Dystrophic Epidermolysis Bullosa. Successful Treatment With Upadacitinib. | Clin Cosmet Investig Dermatol | 2025 | 39867975 | PubTator, text mining | PubMed |
| Repurposing diacerein for the treatment of chronic wounds in recessive-dystrophic epidermolysis bullosa patients by modulating matrix metalloproteinase-9 expression. | J Dermatol | 2025 | 39853777 | PubTator, text mining | PubMed |
| Guanidyl-rich highly branched poly(β-amino ester)s for the delivery of dual CRISPR ribonucleoprotein for efficient large DNA fragment deletion. | J Control Release | 2025 | 39837388 | PubTator, text mining | PubMed |
| Systems immunology integrates the complex endotypes of recessive dystrophic epidermolysis bullosa. | Nat Commun | 2025 | 39809737 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1294/papers?page=7